This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Sarcoidosis of lung with sarcoidosis of lymph nodes림프절의 사르코이드증을 동반한 폐의 사르코이드증 (폐+림프절사르코이드증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D86.2 (Sarcoidosis of lung with sarcoidosis of lymph nodes) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsLung + lymph node sarcoidosis, Sarcoidosis of lung with sarcoidosis of lymph nodes, Scadding stage 2 sarcoidosis (pulmonary infiltrates with hilar lymphadenopathy), pulmonary granulomatosis with hilar and mediastinal lymphadenopathy
C. Adult onsetVery likely to first manifest in adulthood — most commonly manifests in adults aged 25–50; D86.2 is the most common radiographic stage phenotype, corresponding to Scadding stage 2 (56.7% of Korean patients), and combined lung and lymph node involvement in adults is the typical presentation.
1. HistoryHistory of sarcoidosis (see D86.0) + in 1958 Scadding described stage 2 (hilar lymph nodes + pulmonary infiltrates) as the most common stage → Korean studies also confirmed stage 2 as the most frequent stage at 56.7% → the ICD-10 D86.2 classification system explicitly includes this combination.
2. CausesSame as D86.0 and D86.1. Genetic susceptibility (HLA-DRB1, etc.) + environmental antigens (microbes, organic and inorganic dust) → simultaneous granuloma formation in the lung parenchyma and hilar and mediastinal lymph nodes. Tendency toward involvement of both sites simultaneously when the antigen load is large or immune dysregulation is severe.
3. GeneticsPolygenic inheritance (see D86.0 and D86.1). HLA-DRB1*1501 is associated with the phenotype with pulmonary infiltrates of stage 2 or higher. The risk of chronicity and fibrosis may be higher than in D86.0 (lung alone).
4. General epidemiologyScadding stage 2 (lung + lymph nodes) is the most common stage at 56.7% of Korean patients. Stage 2 is also the most common in the West (~30–50%). With accompanying pulmonary infiltrates, the spontaneous remission rate is lower than in stage 1 (50–60%) and the proportion needing treatment is higher. Equal incidence in men and women.
5. PathophysiologyThe mechanisms of D86.0 and D86.1 occur simultaneously. Inhaled antigen → alveolar APC → CD4+ Th1 activation → simultaneous formation of granulomas in the lung parenchyma (centrilobular, peribronchovascular) and within lymph nodes. The greater the granuloma burden, the greater the risk of lung function impairment and fibrosis.
6. SymptomsDry cough, dyspnea (on exertion to at rest), chest pain, fatigue, fever, and weight loss are more frequent than in stage 1. Gas exchange impairment due to bilateral pulmonary infiltrates. Compressive symptoms due to lymphadenopathy (cough, chest discomfort). Severe generalized weakness reflects active granuloma burden.
7. SignsChest X-ray, HRCT: bilateral hilar lymphadenopathy + lung parenchymal nodules, ground-glass opacities, and centrilobular nodules observed together (Scadding stage 2). Pulmonary function: decreased FVC and DLco (more frequent than in stage 1). Elevated serum ACE and sIL-2R. Hypercalcemia may accompany.
8. ScreeningChest X-ray → HRCT → pulmonary function tests (FVC, DLco). Serum ACE, sIL-2R, calcium, IGRA (to exclude tuberculosis). Ophthalmologic examination (uveitis). 6-minute walk test when symptoms are present. PET-CT (to assess the extent of whole-body active involvement).
9. DiagnosisEBUS-TBNA (mediastinal and hilar lymph nodes), TBLB (lung parenchyma), BAL (CD4/CD8 ratio): performing them together maximizes diagnostic yield. Tissue: non-caseating granuloma + exclusion of tuberculosis and fungi. With typical Scadding stage 2 HRCT + elevated ACE + exclusion of tuberculosis, the need for tissue confirmation may be lower.
10. TreatmentFirst line for symptoms or decline in lung function: oral prednisolone. Refractory: methotrexate, azathioprine. Third line: infliximab. Asymptomatic stage 2 with normal lung function: observe for 3–6 months, then decide whether it is progressing. Treatment goals: symptom relief, preservation of lung function, prevention of fibrosis.
11. PrognosisSpontaneous remission rate 50–60% (lower than 80% for stage 1). If it persists for more than 2 years, risk of chronicity and progression to stage 3–4. Many achieve remission with appropriate steroid treatment. Recovery of lung function is key to long-term prognosis. Management of fatigue and reduced quality of life is important.
12. PreventionMinimize occupational dust exposure, smoking cessation. Follow up lung function and chest imaging at 3–6 month intervals. Prevent steroid side effects. Regular electrocardiogram and echocardiography for early detection of pulmonary hypertension and cardiac involvement. Combine pulmonary rehabilitation and exercise therapy.
13. ReferencesBaughman RP et al. A concise review of pulmonary sarcoidosis … and 9 other papers

1. History

D86.2 (pulmonary sarcoidosis with sarcoidosis of lymph nodes) has been recognized as the most central clinical phenotype in the historical development of sarcoidosis. Beginning with Jonathan Hutchinson's first description in 1877, through Caesar Boeck's establishment of the sarcoid concept in 1899 and Jörgen Schaumann's concept of systemic lymphogranulomatosis in 1917, and with the development of chest radiography, the phenotype in which pulmonary infiltrates and hilar lymphadenopathy appear together began to be recognized as the most typical form of sarcoidosis.

In 1958, John Scadding, in proposing the radiographic staging system for the chest, described stage 2 ("radiographic findings of bilateral hilar lymphadenopathy + pulmonary infiltrates") as the most common and clinically important stage of sarcoidosis. This stage 2 is exactly the clinical phenotype corresponding to D86.2. Scadding himself observed a spontaneous remission rate of about 50–60% in stage 2 patients and emphasized the need for clinical criteria to separate cases to be observed without treatment from those in whom steroid treatment is started (PMID: 13526905).

In Korea, a sarcoidosis cohort study published in 2021 (Scientific Reports) confirmed that Scadding stage 2 patients were the most numerous at 56.7% of the total, meaning that D86.2 is the most common phenotype, accounting for more than half of sarcoidosis patients in Korea. Stage 2 is also reported as the most common stage in Western patients, so D86.2 can be regarded as the practical typical phenotype of sarcoidosis. With the spread of EBUS-TBNA since the 2000s, obtaining tissue by accessing thoracic lymph nodes and lung parenchyma at the same time has become standardized, and it has become possible to establish a D86.2 diagnosis with a single bronchoscopic procedure.

In terms of treatment, debate has continued over the criteria for starting steroid treatment in stage 2 patients. Guidelines from the British Thoracic Society (BTS) and American Thoracic Society (ATS) were published in the 1990s, and the principle of prioritizing observation in asymptomatic stage 2 patients with normal lung function and starting steroids in stage 2 patients with symptoms or decline in lung function has been maintained to the present. The 2024 update of the Austrian society guidelines also retained this principle and further emphasized the role of biologics (infliximab, adalimumab) in refractory sarcoidosis.


2. Causes

The cause of D86.2 (lung + lymph node sarcoidosis) is understood on the same basis of systemic granulomatous disease as D86.0 and D86.1. In a genetically susceptible individual, an abnormal CD4+ Th1 cell-mediated immune response to specific environmental antigens persists, forming non-caseating epithelioid granulomas in both the lung parenchyma and the hilar and mediastinal lymph nodes.

The reason pulmonary parenchymal infiltrates appear together with lymphadenopathy is explained by the simultaneous activation of the pathway in which an inhaled antigen is first recognized in the alveoli and then transported to nearby lymph nodes. When the antigen load is large, or when the antigen is widely distributed beyond the lymph nodes into the perilymphatic tissue within the lung parenchyma, pulmonary parenchymal infiltrates occur in addition. As with pulmonary sarcoidosis (D86.0), environmental exposure factors include microbial antigens (Mycobacterium tuberculosis-derived protein, Cutibacterium acnes), organic and inorganic dust, and occupational exposure.

A distinctive feature of D86.2 is that the accompanying pulmonary parenchymal infiltrates may reflect the magnitude of the antigen load or the degree of abnormality in immune regulation. Studies show that patients carrying chronicity-associated alleles such as HLA-DRB1*1501 are more likely to show the phenotype with pulmonary infiltrates of stage 2 or higher. In addition, when drug-induced sarcoid reactions occur in patients using immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4, etc.), they increasingly present in a stage 2 form, so clinical awareness of this cause is important.

Regarding occupational and environmental exposure, in the cohort of New York firefighters who took part in disaster-site recovery work after 9/11, the incidence of sarcoidosis was significantly higher than in the general population, and it has been reported that many presented with accompanying pulmonary infiltrates and lymphadenopathy (corresponding to D86.2). This suggests that combined exposure to dust and chemicals may cause the D86.2 phenotype, which involves the lung and lymph nodes simultaneously.


3. Genetics

D86.2 has the same polygenic background as D86.0 and D86.1, and there is no single causative gene. Among genetic factors, HLA-DRB1 is the most important susceptibility factor in sarcoidosis overall, and there are several important observations regarding the genetic background of the stage 2 phenotype, in which pulmonary infiltrates and lymphadenopathy appear together.

HLA-DRB1*0301 is associated with Löfgren syndrome (acute presentation, including stage 1 hilar lymphadenopathy) and a good prognosis, whereas HLA-DRB1*1501 tends to be associated with a chronic course and the phenotype with pulmonary infiltrates of stage 2 or higher. This means that HLA-DRB1 alleles affect not only whether the disease develops but also the clinical phenotype and prognosis. The ANXA11 (annexin A11) R230C variant is associated with general sarcoidosis risk, and there are some reports that this variant is specifically associated with the phenotype with pulmonary infiltrates, but this is not yet established.

It has been suggested that BTNL2 gene variants, in the form with pulmonary infiltrates, may lead to a more active granuloma-forming response in association with reduced T-cell activation-inhibiting function. Studies also associate the single nucleotide polymorphism at position -308 of the TNF-α promoter (G>A, rs1800629) with sarcoidosis risk and chronicity, and this variant may promote overproduction of TNF-α and contribute to granuloma formation and maintenance. However, the results of these gene association studies have low consistency across ethnicities and study populations, so there are limits to their use for personalized prediction in current clinical practice.

In terms of epigenetics, abnormal DNA methylation patterns have been observed in sarcoidosis lung tissue and immune cells, and it is being studied whether these methylation changes mediate the interaction between environmental exposure and genetic predisposition. At present, genetic testing for the diagnosis of D86.2 is not clinically standardized and is performed for research purposes only.


4. General epidemiology

Scadding stage 2 (with pulmonary infiltrates + lymphadenopathy), corresponding to D86.2, is the most common phenotype among the stages of sarcoidosis. In a Korean patient cohort study, 56.7% of all sarcoidosis patients were Scadding stage 2 at diagnosis (2021, Scientific Reports). Western data also report stage 2 as the most common stage, with proportions in the range of 30–56% depending on the patient population. Therefore, it can be said that more than half of the patients diagnosed with sarcoidosis have the phenotype of simultaneous lung and lymph node involvement corresponding to D86.2.

Age at onset is concentrated in the 20s–50s, as in sarcoidosis overall, and in Korea the proportion of cases in the 50s–60s is also increasing. The sex distribution is equal between men and women, or shows a slightly higher morbidity rate in women. An absolute worldwide prevalence for D86.2 has not been calculated separately, but it can be estimated that about half or more of the overall sarcoidosis prevalence (9.37/100,000 in Korea) corresponds to D86.2.

In terms of spontaneous remission rate, D86.2 shows a spontaneous remission rate of 50–60%, lower than stage 1 (about 80%). This is because the inflammatory burden is greater by the amount of added pulmonary parenchymal infiltrates, and the proportion that becomes chronic without spontaneous remission or progresses to stage 3 or 4 is higher. The proportion of D86.2 patients who start treatment (steroids) is higher than in stage 1, and the proportion of patients achieving remission within 2 years after treatment is reported to be about 50–70%. Cases with no treatment response or persisting for 2 years or longer are classified as chronic sarcoidosis, and a long-term management strategy is established.

Mortality in D86.2 is higher than in stage 1 without pulmonary infiltrates, but statistics classified more specifically than the overall sarcoidosis mortality (9.25/1000) are currently limited. The presence of pulmonary hypertension, pulmonary fibrosis (when progressing to stage 4), and cardiac sarcoidosis are the main factors determining long-term prognosis in D86.2. In Korea, the rate of progression to stage 4 is low at 2.6%, so the overall prognosis of D86.2 patients may be better than in the West.


5. Pathophysiology

The pathophysiology of D86.2 is understood as the simultaneous expression of the mechanisms of D86.0 (lung) and D86.1 (lymph nodes). Inhaled environmental antigens (microbial proteins, organic and inorganic dust) are phagocytosed by resident dendritic cells (DC) and macrophages in the alveoli. These antigen-presenting cells present antigen directly within the lung parenchyma and at the same time migrate through lymphatic vessels to the hilar lymph nodes and present antigen to T cells within the lymph nodes. When these two pathways are activated simultaneously, a CD4+ Th1 cell response is initiated in both the lung parenchyma and the lymph nodes.

Activated CD4+ Th1 cells in the lung parenchyma secrete IL-2, IFN-γ, and TNF-α, differentiating alveolar macrophages into epithelioid cells and forming non-caseating granulomas around the bronchovascular, centrilobular, and interlobular septal regions. These appear on HRCT as centrilobular nodules, peribronchovascular nodules, and ground-glass opacities. In the lymph nodes, granulomas form by the same mechanism, the lymph nodes enlarge, and symmetric hilar and mediastinal lymphadenopathy appears. Granuloma formation at these two sites proceeds simultaneously, producing the typical chest imaging findings of D86.2 (Scadding stage 2).

The reason pulmonary parenchymal infiltrates cause a more severe clinical presentation than stage 1, which has lymphadenopathy only, is that alveolar function is directly impaired. When granulomas involve the gas exchange space within the alveoli, restrictive ventilatory defect and decreased DLco appear. Vitamin D activation due to overexpression of 1α-hydroxylase by macrophages within granulomas also occurs in D86.2 and can cause hypercalcemia and hypercalciuria. High-level secretion of TNF-α and IL-1β causes systemic symptoms such as fever and weight loss, and with chronicity there is a risk of progression to pulmonary fibrosis due to increased TGF-β.

Airway complications can also occur in D86.2. Enlarged hilar lymph nodes may compress the central bronchi from the outside, or sarcoid granulomas within the bronchial mucosa may narrow the airway lumen, worsening cough, wheezing, and dyspnea. On bronchoscopy this can be observed as characteristic mucosal hypertrophy, changes in vascular findings, or airway lumen stenosis, and bronchial mucosal biopsy can confirm granulomas, providing additional diagnostic information.


6. Symptoms

Patients with D86.2 have a higher frequency of symptom onset than those with D86.1 (lymph nodes alone) or stage 1, which is sometimes found asymptomatically. The most common respiratory symptoms are dry cough and dyspnea. It starts as exertional dyspnea and, as symptoms worsen, may appear even at rest. The main mechanism is gas exchange impairment due to pulmonary infiltrates, which is objectively assessed by decreased oxygen saturation on the 6-minute walk test.

Systemic symptoms such as fatigue, malaise, fever, night sweats, and weight loss occur more frequently than in D86.1. Fatigue is one of the symptoms that most reduces quality of life in sarcoidosis patients and is not necessarily proportional to radiologic findings or pulmonary function values. Chest pain or chest discomfort occurs by various mechanisms, such as pleural involvement or lung parenchymal damage and nerve compression by peribronchial granulomas. Rare cases have been reported in which esophageal compression by lymphadenopathy causes dysphagia, or lymphadenopathy around the superior vena cava causes superior vena cava syndrome.

Löfgren syndrome, the acute presentation (bilateral hilar lymphadenopathy + erythema nodosum + arthralgia), may also be accompanied by pulmonary infiltrates, and even in this case the prognosis is generally good. Steroid treatment should be considered when cough worsens, but even if a stage 2 pattern appears in Löfgren syndrome, a spontaneous remission course can be expected first. In patients with D86.2, the presence of concurrent extrapulmonary organ involvement should also be evaluated comprehensively, such as the eyes (uveitis, keratoconjunctivitis sicca), skin (lupus pernio, erythema nodosum), kidneys (glomerulonephritis, nephrocalcinosis), and heart (arrhythmia, conduction disturbance).


7. Signs

The most characteristic imaging sign of D86.2 is the simultaneous observation of bilateral hilar lymphadenopathy + pulmonary parenchymal infiltrates on chest X-ray (Scadding stage 2). The hila enlarge symmetrically on both sides, accompanied by nodules, ground-glass opacities, or reticulonodular opacities in the lung parenchyma. On HRCT, peribronchovascular centrilobular nodules, interlobular septal thickening, ground-glass opacities, and hilar and mediastinal lymphadenopathy are observed together. Nodules tend to be predominantly distributed in the upper and middle lobes, and subpleural distribution is also common.

On pulmonary function tests, abnormal findings are more frequent in D86.2 than in D86.1 (lymph nodes alone). Restrictive ventilatory defect, such as decreased FVC and TLC, and decreased DLco may appear. The FEV1/FVC ratio may decrease if airway stenosis due to peribronchial granulomatous infiltration is present. Serum ACE and sIL-2R tend to be elevated more markedly than in D86.1, owing to the additional contribution of macrophages within lung parenchymal granulomas. Hypercalcemia, hypercalciuria, and elevated serum alkaline phosphatase may accompany. A CD4/CD8 ratio >3.5 in bronchoalveolar lavage (BAL) strongly supports sarcoidosis, and lymphocytosis (>15%) is also characteristic.

On bronchoscopy, cobblestone-like hypertrophy of the bronchial mucosa, perivascular sclerosis, and submucosal nodules may be observed, and granulomas may be confirmed on mucosal biopsy. To assess whether pulmonary hypertension has developed, it is important to measure right ventricular systolic pressure by transthoracic echocardiography. Pulmonary hypertension is more common in stage 4 with pulmonary fibrosis than in D86.2, but it can also occur in stage 2, so appropriate follow-up is necessary.


8. Screening

Initial screening for D86.2 begins with chest X-ray. Further evaluation proceeds when a Scadding stage 2 pattern (bilateral hilar lymphadenopathy + pulmonary infiltrates) is found at a health checkup, or when a chest X-ray abnormality is confirmed in a patient presenting with persistent cough, dyspnea, or fatigue. Chest HRCT is the first additional test, precisely evaluating the distribution, extent, and character of lymphadenopathy and pulmonary parenchymal infiltrates and aiding differentiation from other diseases.

Pulmonary function tests (spirometry, DLco) objectively assess the degree of lung function impairment and are essential for deciding whether to start treatment and for tracking treatment response. Serum ACE, sIL-2R, calcium, creatinine, and liver function tests are performed as the basics. IGRA (QuantiFERON-TB Gold) to exclude tuberculosis is mandatory and is all the more important because the tuberculosis prevalence in Korea is considerable. PET-CT is useful for identifying sites of active whole-body involvement and selecting target sites for biopsy. Electrocardiography and echocardiography are performed to screen for concurrent cardiac sarcoidosis and pulmonary hypertension. Ophthalmologic examination (uveitis) and the 6-minute walk test (assessment of respiratory function) are also included in the initial evaluation.

In D86.2, because lymphadenopathy and pulmonary infiltrates are present simultaneously, differentiation from malignancy (lymphoma, lymph node metastasis of primary lung malignancy), tuberculosis, fungal pneumonia, berylliosis, hypersensitivity pneumonitis, and others can be more complicated than for D86.0 or D86.1. Screening test results should be interpreted by integrating the clinical context, and if suspicion remains, one should proceed to tissue biopsy.


9. Diagnosis

The diagnosis of D86.2 is established when Scadding stage 2 findings (bilateral hilar lymphadenopathy + lung parenchymal infiltrates) are confirmed on chest X-ray and HRCT, non-caseating epithelioid granuloma is demonstrated histologically, and similar diseases such as tuberculosis and fungal infection are excluded. In D86.2, tissue can be obtained from both the lung parenchyma and the lymph nodes, so a combined approach is recommended to maximize diagnostic yield.

A comprehensive bronchoscopic approach is recommended first; performing EBUS-TBNA (hilar and mediastinal lymph nodes), endobronchial biopsy, TBLB (transbronchial lung biopsy), and BAL (bronchoalveolar lavage) all in a single bronchoscopic procedure raises the diagnostic yield to as high as 90% or more. The diagnostic yield of TBLB alone is about 50–60%, but it improves markedly when combined with EBUS-TBNA. A CD4/CD8 ratio >3.5 on BAL cell analysis is a supportive finding that strongly supports sarcoidosis.

It is important to differentiate lymphoma from sarcoidosis through cytology and immunohistochemistry of cell block sections. Lymphoma is excluded by checking the expression patterns of CD20, CD3, Ki-67, BCL-2, and others in the tissue. Infectious granulomas are excluded by acid-fast bacilli (AFB) staining, culture for Mycobacterium tuberculosis and nontuberculous mycobacteria, Grocott silver stain, and fungal culture. When there are typical stage 2 HRCT findings, elevated serum ACE and sIL-2R, and sufficient exclusion of tuberculosis, a clinical diagnosis without tissue confirmation is sometimes accepted, but tissue confirmation is recommended in principle.


10. Treatment

Treatment decisions for patients with D86.2 are based on symptoms and the degree of lung function impairment. If asymptomatic and lung function is normal or mildly decreased, observation at 3–6 month intervals is performed first without immediate drug treatment. Treatment is started if worsening of symptoms, decline in lung function (FVC decrease of 10% or more or DLco decrease of 15% or more), or progression of radiologic findings is confirmed during the observation period.

When treatment is needed, the first-line drug is oral prednisolone. It is generally started at 0.5 mg/kg per day (maximum 40 mg), the response is assessed after 4–6 weeks of treatment, and the dose is gradually tapered. The total treatment duration is mostly 1–2 years. The response to steroids is assessed by decreased granuloma activity (normalization of serum ACE and calcium, improvement on HRCT, improved lung function). Prevention of osteoporosis during steroid treatment (calcium and vitamin D supplementation, bisphosphonates if needed) and blood glucose and blood pressure monitoring are essential.

For second-line treatment, when the patient is refractory to steroids or tapering is needed because of side effects, methotrexate (MTX, 10–15 mg once weekly) or azathioprine (2 mg/kg per day) is added or substituted. These are effective as steroid-sparing agents in reducing steroid side effects during long-term treatment. Hydroxychloroquine is mainly used for managing skin and joint symptoms and hypercalcemia. For refractory D86.2, infliximab (3–5 mg/kg intravenously, at 0, 2, and 6 weeks and then every 8 weeks) has proven effective in RCTs and is used as third-line therapy. Adalimumab can also be used as an alternative. Screening for latent tuberculosis (IGRA) and viral hepatitis before using biologics is essential.


11. Prognosis

The spontaneous remission rate of D86.2 (Scadding stage 2) is about 50–60%, lower than stage 1 (~80%). This is because the accompanying pulmonary parenchymal infiltrates increase the inflammatory burden and make chronicity more likely. Remission mostly occurs within 2 years after diagnosis, and if remission has not occurred after 2 years, it is classified as chronic sarcoidosis and a long-term treatment strategy is established. Steroid treatment is expected to bring faster radiographic improvement and symptom improvement compared with the natural course, but some studies found no significant difference in long-term remission rate between the treated and observed groups, so the debate over the need for treatment in patients without symptoms continues.

The proportion of D86.2 progressing to stage 3 or 4 (pulmonary fibrosis) is estimated at about 10–20%. Risk factors for progression include poor response to treatment, active granulomas persisting for 2 years or more, Black race, carrying the HLA-DRB1*1501 allele, and concurrent involvement of major organs such as the heart and nervous system. In Korean patients, the rate of progression to stage 4 (2.6%) is markedly lower than in the West (5–15%), so the overall prognosis is good. Along with regular follow-up of lung function, it is important to periodically assess whether pulmonary hypertension has developed so that complications are detected early. In terms of quality of life, nonspecific symptoms such as fatigue, dyspnea, and anxiety and depression commonly persist, and comprehensive management of these is needed.


12. Prevention

No primary prevention specific to D86.2 has been established, but avoidance of known risk factors is recommended. It is important to minimize occupational exposure to organic and inorganic dust (firefighting, agriculture, mining, metalworking), wear appropriate respiratory protection, and improve workplace ventilation. Smoking cessation is strongly recommended to preserve lung function.

For secondary prevention after diagnosis, regular follow-up tests (chest X-ray, lung function, serum ACE and calcium) at 3–6 month intervals are key. If symptoms worsen or lung function declines, re-evaluate immediately and start treatment. During steroid treatment, prevention of osteoporosis (calcium and vitamin D supplementation) and monitoring of blood glucose, blood pressure, and weight are performed. Screening for latent tuberculosis (IGRA) must be performed before starting immunosuppressants, and if needed, immunosuppressants are started after preventive anti-tuberculosis treatment. Influenza and pneumococcal vaccination prevent infectious complications. Electrocardiography and echocardiography once a year are recommended for early detection of pulmonary hypertension.

For tertiary prevention, pulmonary rehabilitation programs (exercise therapy, breathing technique training) maintain lung function and improve exercise tolerance. Active evaluation of and support for fatigue and psychosocial symptoms contribute to improved quality of life. Guidance on using the domestic rare disease support system (Special Copayment Reduction V111) and connection to patient support groups help treatment adherence and quality of life.


13. References

  1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573-581. PMID: 21037016
  2. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;2(5261):1165-1172. PMID: 13526905
  3. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155-1167. PMID: 24090799
  4. Song JW, Uh ST, Lee JH, et al. Clinical characteristics and outcomes of Korean patients with sarcoidosis. Sci Rep. 2021;11(1):23845. PMID: 34903788
  5. Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med. 2021;385(11):1018-1032. PMID: 34516024
  6. Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(2):144-157. PMID: 28867799
  7. Gupta D, Dadhwal DS, Agarwal R, Gupta N, Bal A, Aggarwal AN. Endobronchial ultrasound-guided transbronchial needle aspiration vs conventional transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest. 2014;146(3):547-556. PMID: 24675657
  8. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(2):76-89. PMID: 19382584
  9. Rossides M, Kullberg S, Eklund A, Grunewald J, Arkema EV. Sarcoidosis mortality in Sweden: a population-based cohort study. Eur Respir J. 2018;51(2):1701815. PMID: 29467202
  10. Park HJ, Jung JI, Chung MH, et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003–2015. Respir Med. 2018;136:122-126. PMID: 29501251